Sign in Subscribe

kras

A collection of 116 issues

KRAS and BRAF Hotspot Mutations Show Lower Prevalence in Bangladeshi CRC Patients

Skip to content The CRC Digest KRAS and BRAF Hotspot Mutations Show Lower Prevalence in Bangladeshi CRC Patients Targeted sequencing of 46 Bangladeshi colorectal cancer samples found KRAS mutations in 10.87% of cases (including G12D, G12V, and G13D variants) and no BRAF V600E mutations, a notably lower prevalence than

CRC Research Update — September 25, 2026

Today's colorectal cancer research highlights

KRAS mutations occur in 40% of colorectal cancers and predict resistance to anti-EGFR therapy

Skip to content The CRC Digest ◇ RESEARCH KRAS mutations occur in 40% of colorectal cancers and predict resistance to anti-EGFR therapy A comprehensive review finds KRAS-mutant tumors are associated with increased recurrence risk and reduced survival, including in patients undergoing liver metastasis surgery. (Current Oncology) This content is informational only

CRC Research Update — September 24, 2026

Today's colorectal cancer research highlights

CRC Research Update — September 21, 2026

Today's colorectal cancer research highlights

Hereditary Syndromes Account for Only 20-25% of Early-Onset Cases

Skip to content The CRC Digest ◇ RESEARCH Hereditary Syndromes Account for Only 20-25% of Early-Onset Cases A comprehensive review reports that hereditary cancer syndromes account for 20-25% of early-onset colorectal cancer cases, with most occurring in the absence of known genetic predispositions. (Oncology Therapy) This content is informational only and

Early-Onset CRC Shows Distinct Molecular Features, Gut Microbiome Implicated

Skip to content The CRC Digest ◇ RESEARCH Early-Onset CRC Shows Distinct Molecular Features, Gut Microbiome Implicated A systematic review finds that most early-onset colorectal cancer cases occur without known genetic predispositions, and emerging evidence points to the gut microbiome as a potential contributor. (Oncology Therapy) This content is informational only

CRC Research Update — September 20, 2026

Today's colorectal cancer research highlights

PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors

Skip to content The CRC Digest ◇ RESEARCH PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors Researchers identified PADI1 and PADI3 as negative prognostic markers in KRAS-mutant colorectal and pancreatic cancers; pharmacological inhibition of PADIs synergizes with KRAS inhibitors in preclinical models and restores sensitivity in resistant cells. (Cell Rep) This

CRC Research Update — September 18, 2026

Today's colorectal cancer research highlights